Hyperactivation of Akt pathway in cancer occurs most commonly through gain-of-function mutations in PI3-kinase or loss-of-function mutations in PTEN phosphatase (Lee et al., 2018; Shariati and Meric-Bernstam, 2019; Yang et al., 2019), but oncogenic Akt mutations are also observed in 2–5% of many solid tumors. Here, AKT1 is linked to cancer.